D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
AXSM holding history
Axsome Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
AXSM overviewAll 13F holders of AXSMFull Q2 2026 holdings
- Shares (Q2 2026)
- 604,753
- Value
- $148.0M
- % of portfolio
- 0.1%
- Quarters held
- 16
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 604,753 | $148.0M | 0.1% | +1,288+0.2% | Added | Holders |
| Q1 2026 | 603,465 | $102.0M | 0.1% | +54,352+9.9% | Added | Holders |
| Q4 2025 | 549,113 | $100.3M | 0.1% | +252,826+85.3% | Added | Holders |
| Q3 2025 | 296,287 | $36.0M | <0.1% | +95,523+47.6% | Added | Holders |
| Q2 2025 | 200,764 | $21.0M | <0.1% | −346,901−63.3% | Reduced | Holders |
| Q1 2025 | 547,665 | $63.9M | 0.1% | +527,319+2,591.8% | Added | Holders |
| Q4 2024 | 20,346 | $1.72M | <0.1% | +17,446+601.6% | Added | Holders |
| Q3 2024 | 2,900 | $260.6K | <0.1% | −3,434−54.2% | Reduced | Holders |
| Q2 2024 | 6,334 | $509.9K | <0.1% | −1,435−18.5% | Reduced | Holders |
| Q1 2024 | 7,769 | $620.0K | <0.1% | −1,415−15.4% | Reduced | Holders |
| Q4 2023 | 9,184 | $731.0K | <0.1% | +9,184 | New | Holders |
| Q3 2022 | 0 | $0 | 0.0% | −6,762−100.0% | Sold out | Holders |
| Q2 2022 | 6,762 | $259.0K | <0.1% | −148,630−95.6% | Reduced | Holders |
| Q1 2022 | 155,392 | $6.43M | <0.1% | +155,392 | New | Holders |
| Q4 2021 | 0 | $0 | 0.0% | −13,939−100.0% | Sold out | Holders |
| Q3 2021 | 13,939 | $459.0K | <0.1% | −9,110−39.5% | Reduced | Holders |
| Q2 2021 | 23,049 | $1.55M | <0.1% | −10,169−30.6% | Reduced | Holders |
| Q1 2021 | 33,218 | $1.88M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.